|

The Role of 18F-FDG&68Ga-FAPI PET/CT in the Assessment of Conversion Therapy Efficacy in Gastric Cancer with Peritoneal Metastasis.

RECRUITINGSponsored by Ruijin Hospital
Actively Recruiting
SponsorRuijin Hospital
Started2024-06-15
Est. completion2028-03-31
Eligibility
Age18 Years+
Healthy vol.Accepted
View on ClinicalTrials.gov →

NCT06597526

Summary

This study aims to investigate the value of 18F-FDG\&68Ga-FAPI PET/CT in evaluating the outcome of conversion therapy and the prognosis of people with peritoneal metastases from gastric cancer.

Eligibility

Age: 18 Years+Healthy volunteers accepted
Inclusion Criteria:

1. Histologically confirmed gastric adenocarcinoma with no history of resection of primary or metastatic lesions
2. Peritoneal metastases of gastric cancer requiring laparoscopy for definitive diagnosis without gastric outflow tract obstruction and intestinal obstruction
3. Patients voluntarily enrolled in this study by signing an informed consent form
4. Age ≥ 18 years
5. Eastern Cooperative Oncology Group (ECOG) score ≤ 2,
6. Expected life expectancy ≥ 3 months
7. Adequate organ and bone marrow function
8. Willingness to adhere to the study protocol and follow-up programme

Exclusion Criteria:

1. Signs of distant metastases other than peritoneal metastases at enrolment
2. Pregnant or breastfeeding women.
3. Patients with a history of other malignant diseases in the last 5 years, except cured skin cancer and carcinoma in situ of cervix
4. Severe mental disease, uncontrolled epilepsy, or central nervous system disease

Conditions3

CancerGastric CancerPeritoneal Metastasis

Browse More Trials

Cancer trials

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.